Skip to main content

Table 1 Significant changes in TET2-target gene expression associated with prostate cancer development and progression

From: Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progression

Gene

Tumor vs normal1

Matched tumor and normal

Tumor vs normal1

All TCGA tumors

Recurrence1

Stage1

Gleason score (overall)2

GS6 vs GS73

GS6 vs GS8 +3

GS7 vs GS8 +3

ASB2

2.9543E−08

1.1163E−10

0.0189

0.0095

3.1843E−05

0.17

0.00044413

2.1003E−4

ETNK2

8.0425E−15

1.6991E−16

0.0147

0.3725

0.1526

1

0.4005

0.0924

KCNJ15

1.1797E−09

6.9856E−14

0.0436

0.6534

0.0842

0.4247

1

0.0487

MEIS2

8.6435E−09

1.4128E−13

0.0125

0.0256

0.0010

0.5208

0.0100

0.0015

NRG1

1.6456E−05

1.9533E−11

0.0013

0.0023

0.0016

1

0.0918

6.6543E−4

NTN1

3.1531E−05

1.1782E−07

0.0091

0.0261

0.0273

1

0.205

0.0139

NUDT10

2.4896E−08

2.8735E−10

0.0235

0.5739

0.4542

0.4667

0.3151

0.9259

PDE4A

2.1250E−09

1.2586E−12

0.0431

0.6292

0.5444

0.9831

1

0.4186

SRPX

1.0079E−05

3.2133E−08

0.0078

0.0014

1.1851E−07

1

0.0014

8.9930E−08

  1. Bolded and underlined numbers represent significant p values as derived from 1Mann-Whitney U test, 2Kruskal-Wallis test, and 3Bonferroni-adjusted Dunn test
Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us